Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

DiscoveRx Corporation Acquires Bioseek

Published: Thursday, November 08, 2012
Last Updated: Thursday, November 08, 2012
Bookmark and Share
DiscoveRx adds primary cell assays to its portfolio of drug discovery solutions.

BioSeek’s phenotypic screening technology improves the success rate of pharmaceutical research and development by integrating primary cell profiling into the drug discovery process. The proprietary BioMAP® systems incorporate primary human cell-based disease models that generate predictive biological activity profiles for potential drugs. As a result, the technology drives the selection and development of new drug candidates and safer chemicals.

BioSeek, formerly part of the Asterand Company, has an established customer and partner base of pharmaceutical and biotech customers. Recently it was a recipient of a $46,770,000 grant award from EPA Toxcast® program for the use of BioSeek's human primary cell assay platform to help predict the biological activity and potential toxicity of up to 60,000 additional samples, including environmental chemicals, pesticides, failed pharmaceuticals and nanomaterials.

"The integration of Bioseek provides two new capabilities to DiscoveRx Corporation," said Pyare L. Khanna, President and Chief Executive Officer of DiscoveRx Corporation. "Expertise in primary cell disease models as well as a highly differentiated compound characterization service. These new capabilities further strengthen our position as a premier drug discovery solution provider that develops and commercializes high-value products and specialized services."

“BioSeek has become an integral part of the pharmaceutical industry's drug discovery programs, and in joining DiscoveRx, it will gain the opportunity to expand the utility of BioMap technology platform even further,” said Jack Davis, Chairman and CEO of Asterand.

The acquisition represents another significant step in DiscoveRx strategy to provide next generation drug discovery solutions through internal development and strategic acquisitions. DiscoveRx is committed to making this a seamless integration with no interruption of services to BioSeek Customers. The financial terms of the deal are not being disclosed.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Validation of Drug Toxicity Prediction using DiscoveRx Model
BioMAP® Systems was shown to identify important safety aspects of drugs and chemicals more efficiently and accurately than can be achieved by animal testing.
Tuesday, May 20, 2014
Scientific News
Salford Lung Study - The First Real World Clinical Trial
In this podcast, we learn about the Salford Lung Study and its potential to revolutionize the way we assess new drugs and treatments around the world.
Editing Gene Mutations in Anemia
Researchers successfully use a new gene editing strategy to correct mutations that cause a form of anemia.
Nanomedicine Aims to Improve HIV Drug Therapies
New research aims to improve the administration and availability of drug therapies to HIV patients using nanotechnology.
Observing Direct Inheritance of Gene-Silencing RNA
Research has allowed for the observation of double-stranded RNA molecule being passed from parent to offspring in roundworms.
Fighting Cancer with Immune Response
New treatment elicits two-pronged immune response that destroys tumors in mice.
First Entirely 3D-printed Organ-on-a-Chip with Integrated Sensors
New approach to manufacturing may allow researchers to rapidly design organs-on-chips that match the properties of a specific disease or individual patient's cells.
Nanoparticles Offer Promising Platform for Flavivirus Treatment
New nanoparticle effectively vaccinated mice against one dengue strain and could be created to target all four.
Study Finds Key Regulator in Pulmonary Fibrosis
Researchers identify an enzyme that could open the way to therpies for chronic fatal lung disease.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Ovarian Cancer Insight
Study showed tumours release cytokines to attract macrophages, which secrete growth factors that in turn promote tumour growth.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos